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Network connectivity determines cortical thinning
in early Parkinson’s disease progression
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B. Mišić1, D.L. Collins1 & A. Dagher 1
Here we test the hypothesis that the neurodegenerative process in Parkinson’s disease (PD)
moves stereotypically along neural networks, possibly reflecting the spread of toxic alpha-
synuclein molecules. PD patients (n= 105) and matched controls (n= 57) underwent T1-MRI
at entry and 1 year later as part of the Parkinson’s Progression Markers Initiative. Over this
period, PD patients demonstrate significantly greater cortical thinning than controls in parts
of the left occipital and bilateral frontal lobes and right somatomotor-sensory cortex. Cortical
thinning is correlated to connectivity (measured functionally or structurally) to a “disease
reservoir” evaluated by MRI at baseline. The atrophy pattern in the ventral frontal lobes
resembles one described in certain cases of Alzheimer’s disease. Our findings suggest that
disease propagation to the cortex in PD follows neuronal connectivity and that disease spread
to the cortex may herald the onset of cognitive impairment.
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The network-spread hypothesis proposes that neurodegen-erative diseases target intrinsic brain networks. Specifically,it is suggested that the progression of disease follows net-
work connectivity and that neurotoxicity is caused by the spread
and accumulation of toxic agents along the brain’s neuronal
connectome1,2. In the case of Parkinson’s disease (PD), the likely
agent is misfolded α-synuclein (α-syn). In its normal conforma-
tion, α-syn is an endogenous protein that is soluble and con-
tributes to synaptic vesicular function3; however, in
synucleinopathies such as PD, α-syn is present in a hyperpho-
sphorylated and insoluble state and found to adopt an abnormal
configuration into amyloid fibril aggregates4. A model first pro-
posed by Braak suggested that patterns of abnormal α-syn
accumulation observed at postmortem were consistent with a
stereotyped propagation from brainstem to subcortical areas to
cortex, which paralleled the clinical progression of the disease5.
Numerous lines of evidence support this model: misfolded α-syn
aggregates are identified at postmortem in the brains of PD
patients, and the protein has been shown to spread through
neuroanatomical pathways causing cell death in animal models
due to its neurotoxicity4; however, the model remains con-
troversial and direct human evidence is sparse6,7.
There is currently no imaging technique that allows in vivo
measurement of α-syn in the brain. However, we previously
observed a pattern of brain atrophy in cross-sectional magnetic
resonance imaging (MRI) scans of de novo PD patients from the
Parkinson’s Progression Markers Initiative (PPMI) database8 that
was consistent with the network-spread hypothesis9. The regional
distribution of atrophy identified using deformation-based mor-
phometry (DBM) overlapped with an intrinsic connectivity net-
work, and the pattern suggested a disease epicenter in the
substantia nigra. The atrophy distribution was mostly subcortical,
involving brainstem, striatum, thalamus, and medial temporal
lobe.
Recent studies using voxel-based morphometry (VBM) to
assess gray matter density have begun to highlight a pattern of
cortical changes in PD10,11, but there have been discrepant
findings12,13. Inconsistencies are not only due to heterogeneity in
disease progression and small sample sizes, but also to metho-
dological issues14. Cortical thickness analysis may be better able
to delineate cortical morphometrical patterns and may be more
sensitive to age or disease-related regional gray matter changes
than VBM15,16. While cortical thinning is normal in the aging
process17, deviations from typical patterns can be used as diag-
nostic indicators for neurodegenerative disorders (e.g., Alzhei-
mer’s disease (AD)) even at early stages18. Several cross-sectional
studies of MRI-derived cortical thickness in early-stage PD have
reported cortical thinning in parietal and premotor regions
compared to controls16,19–21. Moreover, cortical thinning appears
to correlate with poorer cognitive performance22. However, cor-
tical thickness in PD has yet to be studied in a controlled long-
itudinal setting, and little is known as to how it may correlate
with other disease-related measures.
Disease spread to cortical areas may be accompanied by the
start of cognitive impairment. Dementia is now recognized as a
common, perhaps inevitable, feature of PD23,24. Cognitive
impairment takes several forms, starting with executive (frontal
lobe) dysfunction and apathy, and progressing to visual halluci-
nations, impulse control, and behavioral disorders, and, even-
tually, a global cognitive impairment that resembles AD24–27. As
with the classical dementias, it is likely that the specific pattern of
disease spread in PD may shape the clinical features of the
dementing process1.
Here we take advantage of follow-up imaging in a large long-
itudinal, multicenter study that aimed to assess the progression of
clinical features, imaging, and other biomarkers in a cohort of
well-characterized de novo PD patients. Using the PPMI database
(http://www.ppmi-info.org/data), we test the theory that disease
progression at a 1-year follow-up, as assessed by cortical thick-
ness, is best explained by spread from a “disease reservoir” along
the brain’s connectome. We further identify certain factors at
baseline that predict severity of disease progression at follow-up
and provide evidence that cortical involvement might herald the
onset of cognitive decline.
Results
Participants. Participants in the present study consisted of de
novo PD patients (n = 105) and healthy controls (HC, n = 57)
enrolled in the PPMI study8 [accessed May 01, 2016), clin-
icaltrials.gov identifier NCT01141023] who had follow-up
assessment 1-year postenrollment (1.05 years for both groups).
Demographic and clinical data are summarized in Table 1. PD
patients were unmedicated at the first evaluation. At 1-year fol-
low-up, 81 of the 105 were on PD medication (e.g., levodopa or
dopamine agonist). Among PD patients, performance on the
Montreal Cognitive Assessment (MoCA) was slightly worse at
follow-up compared to baseline (from 27.5 to 26.7, t(103) = 3.038,
p = 0.003). PD patients also scored higher on the Movement
Disorders Society Unified Parkinson’s Disease Rating Scale Part
III (UPDRS-III) at follow-up compared to baseline, but this did
not reach statistical significance (from 21.7 to 23.1, t(95) = −1.544,
p = 0.126).
Changes in cortical thickness at 1-year follow-up. Over the 1-
year period, mean whole-brain cortical thickness significantly
decreased among both PD patients (t1 = 3.055 mm± 0.013; t2 =
3.027 mm± 0.013) and controls (t1 = 3.055 mm± 0.016; t2 =
3.036 mm± 0.017) (both p< 0.01). Regional cortical thinning was
greater in PD than HC (Fig. 1). Specifically, four significant
clusters were identified: (1) left occipital and inferior and middle
temporal gyri, (2) left frontal, (3) right frontal, and (4) right pre-





t1 61.06± 9.37 59.05± 10.96 1.224 0.223
t2 62.11± 9.37 60.10± 10.96 1.223 0.223
Sex 33 F: 72 M 22 F: 35 M 0.846 0.358
UPDRS-III
t1 21.67± 9.61 — — —
t2 23.10± 10.67 — — —
MoCA
t1 27.49± 2.11 28.30± 1.13 −3.162 0.002










373.36± 92.53 −0.189 0.850
t-tau
t1 44.77± 18.36 46.06± 19.69 −0.407 0.684
p-tau181
t1 15.85± 9.74 17.30± 9.84 −0.885 0.377
t1 measures at entry, t2 measures at 1-year follow-up. Values are expressed as mean± standard
deviation. Two rightmost columns refer to the difference between PD and controls. All
cerebrospinal fluid measures are expressed in pg/ml
UPDRS-III Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part III, MoCA
Montreal Cognitive Assessment, α-syn α-synuclein, Aβ42 β-amyloid 1–42, t-tau total tau, p-tau181
phosphorylated tau
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and post-central gyrus and supramarginal gyrus (Fig. 2). The
frontal lobe atrophy mostly involved the inferior parts of lateral
and medial frontal cortex, including the orbitofrontal cortex,
frontal pole, ventromedial, and rostral dorsomedial prefrontal
cortex. On the lateral surface, inferior and medial frontal gyri
were implicated, with extension to the superior frontal gyrus on
the left. In order to assess the likely functional consequences of
cortical thinning in PD, we assigned each cortical parcel to one of
the seven intrinsic brain networks derived from resting-state
functionl MRI (fMRI) by Yeo et al.28. Cortical regions belonging
to the limbic, frontoparietal, and ventral attention networks on
average demonstrated the greatest cortical thinning, as well as
anterior parts of the default mode network (DMN; Fig. 3). There
were no areas showing greater loss of cortical thickness in HC
than in PD.
Connectivity and disease propagation. The disease propagation
hypothesis predicts that cortical brain atrophy at follow-up should
depend on connectivity of cortical areas to affected areas at
baseline. We had previously shown predominant subcortical
atrophy in de novo PD in this population. Connectivity between
any cortical area and this putative subcortical “disease reservoir”
should therefore predict the degree of cortical thinning relative to
age-matched controls when comparing follow-up to baseline. We
define the disease reservoir as the subcortical areas showing
atrophy in PD patients relative to controls at the initial evaluation,
as determined previously using DBM9. For the current analysis,
the brain was segmented into 463 cortical and subcortical regions
of interest29. Each surface vertex from the cortical thickness
images was mapped to the nearest volumetric parcel (see Methods
section). To examine the propagation hypothesis, the connectivity
(Connij) between any cortical parcel i and any parcel belonging to
the disease reservoir j was measured. Here we calculated Connij
based on healthy brain connectomes (see Methods section). The
analysis was performed for the whole brain and for each hemi-
sphere separately using Spearman’s correlation to examine the
relation between disease progression and exposure. Disease
exposure was defined as the product of connectivity and atrophy
measure in the corresponding disease reservoir region j at the
onset of the disease, summed over all possible connections.




Both functional and structural connectivity were used to test
the propagation hypothesis (Fig. 4). Connectomes were generated
using data from young healthy individuals to calculate the Connij.
Atrophy(j) was set equal to the z-value at each region j of the
independent component demonstrating atrophy in PD compared
to HC from the previously computed DBM map from the
baseline MRI9. Note that for areas not showing significant
atrophy at baseline the value of Atrophy(j) is equal to 0.
First, a functional connectome was generated using resting-state
fMRI to define Connij. Significant correlation was observed
between regional cortical thinning and disease exposure (r = 0.19,
p< 0.0001). Significance was confirmed by permutation testing
where we kept the connectivity structure (i.e., subcortical–cortical
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Fig. 1 Cortical thinning in PD. Changes in cortical thickness in PD patients compared to healthy controls over the 1-year study period. Left panel: t-statistic
comparing PD to HC at baseline and follow-up [(PD2-PD1)–(HC2-HC1)], at each cortical vertex. Right panel: thresholded map showing areas of significant
difference. Cluster-corrected p-value in blue
Fig. 2 Significant clusters of cortical thinning in PD. Four peak clusters of
cortical thinning in PD were identified in parts of (1) left occipital lobe
(nverts= 1081 [5.53 resels], p< 0.0001, (2) left frontal lobe (nverts= 2115
[10.99 resels], p< 0.0001), (3) right frontal lobe (nverts= 3720 [15.79
resels], p< 0.0001), and (4) right somatomotor cortex (nverts= 1990
[16.56 resels], p< 0.0001). nverts: number of vertices in the significant area
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(n = 10,000) and the 95% confidence interval was measured using
bootstrapping (n = 10,000) (r ∈ [0.11,0.28], p_perm< 0.0001).
Moreover, cortical thickness of both the left (r = 0.22, p = 0.0005,
r ∈ [0.09,0.34], p_perm = 0.0004) and right hemisphere (r = 0.27, p
< 0.0001, r ∈ [0.16,0.38], p_perm< 0.0001) significantly correlated
with the disease exposure from bilateral affected regions.
Second, the same hypothesis was tested using structural
connectivity as measured by diffusion-weighted MRI (DW-
MRI). Though the correlation was not significant at the whole-
brain level (r = −0.03, p = 0.239, r ∈ [−0.12,0.06], p_perm = 0.762),
change in cortical thickness and disease exposure within the
individual hemispheres were significantly correlated. Similar
results were observed within the left hemisphere (r = 0.14,
p = 0.016, r ∈ [0.01,0.27], p_perm = 0.016) and the right hemi-
sphere (r = 0.11, p = 0.044, r ∈ [−0.02,0.25], p_perm = 0.041).
Failure to capture the relationship at the whole-brain level may
be due to inherent limitations in DW-MRI to detect interhemi-
spheric connectivity30–33 (See Discussion section).
For comparison, when only considering pure Euclidean
distance, we found that cortical thickness of neither the whole
brain (r = −0.06, p = 0.104, r ∈ [−0.15,0.03], p_perm = 0.105) nor
the left hemisphere (r = −0.09, p = 0.088, r ∈ [−0.22,0.04], p_perm
= 0.084) correlated with the disease exposure from bilateral-
affected regions. However, when only considering the right
hemisphere, we observed significant results (r = −0.21, p = 0.0007,
r ∈ [−0.33,−0.09], p_perm = 0.0006).
Furthermore, we tested the relative contribution of functional and
structural networks to disease spread using a multivariate model for
each hemisphere. Within the left hemisphere, the analysis shows that
both functional connectivity (β = 0.18, t(220) = −3.88, p< 0.001) and
structural connectivity (β = 0.04, t(220) = −2.27, p = 0.02) significantly
relate to cortical atrophy. Within the right hemisphere, again
functional connectivity (β = 0.12, t(220) = −2.56, p = 0.01) and
structural connectivity (β = 0.08, t(220) = −2.77, p< 0.01) significantly
relate to cortical atrophy. These results suggest that both types of
connectivity play a role in the disease-spread model; however,
functional connectivity appears to be more significant.
As a follow-up exploratory analysis, we tested whether striatal
and non-striatal regions within our disease reservoir may
contribute differently to disease exposure. Based on functional
connectivity, analysis restricted to a basal ganglia reservoir
showed an increased effect size within the left hemisphere (r =
0.29, p< 0.0001, r ∈ [0.16,0.40], p_perm< 0.0001), right hemi-
sphere (r = 0.37, p< 0.0001, r ∈ [0.26,0.47], p_perm< 0.0001),
and across the whole rain (r = 0.29, p< 0.0001, r ∈ [0.21,0.37],
p_perm < 0.0001) compared to the analysis using all affected
subcortical regions. When repeating this analysis for structural
connectivity, the effect size observed for a basal ganglia-restricted
analysis within the left hemisphere (r = 0.14, p = 0.016, r ∈
[0.01,0.27], p_perm = 0.017), right hemisphere (r = 0.15, p =
0.012, r ∈ [0.01,0.28], p_perm = 0.011), and across the whole
brain (r = 0.02, p = 0.35, r ∈ [−0.08,0.11], p_perm = 0.35) were
similar to the analyses considering all subcortical structures.
Relation to cognition and cerebrospinal fluid (CSF) measures.
Additional analyses restricted to the PD group were performed to
investigate the relationship between cortical thinning of the four
identified clusters and other disease-related measures (Fig. 5). To
test whether CSF measures may contribute to the cortical thin-
ning within each of the clusters, we conducted partial correlations
(controlling for age and gender). We found that changes in the
left frontal (r = −0.16, p = 0.05) and left occipital cluster (r = −0.18,
p = 0.037) both correlated negatively with CSF Aβ42. Changes of
the left occipital cluster (r = 0.17, p= 0.043) also correlated with
CSF α-syn. We then performed a linear regression model to
examine whether cortical thinning was related to cognitive
decline (as assessed by MoCA) and found the overall model,
controlling for covariates, was significant (r2 = 0.12, p = 0.03).
Further post-hoc analysis revealed that only the cortical thinning
of the left frontal cluster (r = −0.19, p = 0.03) significantly related
to MoCA changes. Note that these analyses fail to survive cor-
rection for multiple comparisons of the four significant clusters.
CSF measures did not correlate with individual time point
measures nor changes in MoCA or motor severity as assessed by
UPDRS-III (all p> 0.05). No significant correlation was observed
between cortical thickness of any of the four clusters and
measures of UPDRS-III or p-tau181. In the control group, no
significant correlations between cortical thickness and measures































Visual Somatomotor Dorsal attention Ventral attention Limbic Frontoparietal Default
Fig. 3 Intrinsic networks affected by cortical thinning. Cortical thinning in PD vs HC in the seven intrinsic brain networks of Yeo et al.27. All seven
intrinsic brain networks demonstrated significant cortical thinning with p< 0.0001 (permutation test n= 10,000): visual network (μ ¼ 0:63;95%
CI 2 ½0:46;0:81), somatomotor network (μ ¼ 0:53;95% CI 2 ½0:37;0:69), dorsal attention network (μ ¼ 0:52;95% CI 2 ½0:32;0:73), ventral attention
network (μ ¼ 0:86;95% CI 2 ½0:67; 1:94), limbic network (μ ¼ 1:2;95% CI 2 ½0:98; 1:40), frontoparietal network (μ ¼ 1:05;95% CI 2 ½0:80; 1:28), and
default mode network (μ ¼ 0:73; 95% CI 2 ½0:57;0:88). + outliers within each network.
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Discussion
The present study investigated 105 PD and 57 control partici-
pants over a 1-year period following initial diagnosis. Early
PD progression was associated with significant cortical
changes. While aging was also associated with cortical thinning,
PD patients demonstrated significantly greater reduction in
cortical thickness than controls (0.028 mm vs 0.019 mm
reduction on average). This was observed mostly in parts of
the left occipital and bilateral frontal lobes and right
somatomotor-sensory cortex—regions largely belonging to the
limbic, frontoparietal, ventral attention, and default mode
networks.
Right hemisphereLeft hemisphere
r = 0.27r = 0.22
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Fig. 4 Testing the propagation model. a Schematic of the propagation model. The model used a disease reservoir (colored regions) consisting of
15 subcortical regions of interest and connectivity from each region to the cortical surface. b PD-specific atrophy map used to define disease “content” in
each region of interest of the disease reservoir, derived from deformation-based morphometric analysis of patients at baseline (modified from Zeighami
et al. 2015). c–e Correlation between cortical thinning (average t-values, PD–HC, t2–t1) of each cortical region and disease exposure (see text for detail).
Connectivity based on functional resting state data in the c left and d right hemisphere as well as connectivity based on diffusion-weighted data in the e left
and f right hemisphere are depicted
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We tested the theory that neurodegeneration in PD results
from a disease-spreading process that enters the cerebral cortex
from initially affected subcortical areas. Per the network propa-
gation hypothesis, neurodegenerative diseases result from the
aggregation and propagation of misfolded proteins, which in turn
results in neuronal death and brain atrophy2,4. The distribution of
focal cortical thinning should therefore be contingent on con-
nectivity to already affected areas, which we call a “disease
reservoir” by analogy to the spread of epidemics in populations.
In the present study, we tested this hypothesis in PD with long-
itudinal data. We found that cortical regions with greater con-
nectivity (measured functionally or structurally) to the subcortical
disease reservoir identified at the time of diagnosis demonstrated
greater cortical atrophy over the 1-year period. This is in line with
our previous work using DBM in the initial scan from this
dataset9, which indicated that regions demonstrating the greatest
atrophy were those belonging to a connectivity network with an
epicenter in substantia nigra—the hypothesized origin of mis-
folded protein spread to the supratentorial cerebrum in PD.
Some aspects of our model deserve mention. Predictions based
on physical distance were similar to topographical distance based
on DW-MRI in the right hemisphere. This may be a result of the
known distance bias of probabilistic tractography31 or that the
brain is organized such that neuronal connectivity correlates with
Euclidean distance32. Resting-state connectivity, however, better
predicted atrophy than tractography or topographical distance,
thus supporting the notion that connectivity improves our mea-
sure of propagation above and beyond consideration of geome-
trical distance alone. Moreover, there is no described mechanism
by which a protein spreads physically through the neuropil.
While functional connectivity models fit the data at a whole-brain
level, we only observed a relationship between connectivity and
thinning in individual hemispheres when using a DW-MRI
connectome. This is perhaps due to inherent limitations in DW-
MRI to capture interhemispheric connections33. Finally, the dis-
ease exposure analysis limited to the basal ganglia only yielded
greater effects on cortical thinning than the whole subcortical
reservoir model. This might suggest a greater contribution of
basal ganglia to cortical propagation, although our results do not
unequivocally demonstrate this. Mathematical models of the
dynamic spread through brain networks, accounting for factors
such as protein accumulation and clearance, have been proposed
in recent years for AD34–36. Such models might be usefully
applied to PD.
In our post-hoc analysis, greater reduction in cortical thickness
of the left frontal cluster in PD over the 1-year period was
associated with worsening cognition (as assessed by the MoCA),
although the p-value of 0.03 would not survive correction for
multiple comparisons. This mirrors results from other studies
that have similarly found trending results22,37. While dementia is
rare in early PD, especially as our cohort was selected to exclude
dementia at baseline, we still see greater cortical thinning of
frontal clusters in the PD group 1-year postdiagnosis. Cortical
neuronal degeneration could be occurring earlier in the clinical
course of PD than once thought. Although PD is primarily
thought of as a movement disorder, it is recognized to be a brain-
wide neurodegenerative process that spreads up from brainstem
into cortex, as originally suggested by Braak38.
In this dataset, only cortical thinning of the left frontal cluster
related to cognitive decline. Furthermore, thinning in this frontal
cluster was weakly related to reduced Aβ42 at baseline (Fig. 5).
Lower CSF Aβ42 and α-syn was also associated with occipital
thinning, which did not correlate with cognitive decline. The
frontal clusters demonstrating greater loss of cortical thickness in
PD involved lateral and medial frontal cortex, predominantly in
ventral and orbitofrontal areas. These regions of frontal lobe
belong to the limbic system, the frontoparietal systems implicated
in focused attention, and the DMN implicated in memory
retrieval. This pattern of frontal atrophy is similar to that
described in a subgroup of AD patients identified by hierarchical
clustering39 and in patients with behavioral variant fronto-
temporal dementia1. A notable difference between the pattern of
cortical atrophy described here and that commonly seen in AD is
the relative absence of more posterior involvement (precuneus,
posterior cingulate, and parietal lobe) in our PD cohort. The
effect seen here is much more anterior, possibly reflecting the
propagation of disease via dopaminergic or frontostriatal pro-
jections. Nonetheless, the DMN is also disrupted in AD40,41 and a
target of amyloid plaques42. The anterior DMN may be an avenue
through which dementia develops in PD. We note also that, in the
Braak model of AD, the initial cortical site of amyloid-β invol-
vement is the ventral frontal cortex43 and that the observed
ventral frontal atrophy pattern in PD shows a high degree of
similarity to early Aβ42 deposition measured by positron emission
tomography in AD44.
While cognitive impairment is a recognized consequence of
PD23, its underlying mechanism is not well understood. Our
findings suggest that, in the PD group, higher Aβ42 deposition in
the brain at baseline (indicated by lower CSF Aβ42 levels45)
predicted greater cortical thinning of the left frontal cluster over
the 1-year period. Though our results are not conclusive, they
suggest that Aβ42 may make the PD brain more susceptible to
cortical thinning and, in turn, more prone to cognitive decline.
Indeed, recent positron emission tomographic studies have
revealed that cortical amyloid deposits are associated, in a dose-
dependent manner, with increased risk for cognitive decline in
PD46. Additionally, low CSF Aβ42 has previously been associated
with the risk of subsequent dementia in PD47. These findings
provide evidence in favor of potentially overlapping mechanisms
for dementia in PD and AD. Previous research found that 28% of
PD patients have AD pathological features at postmortem48.
While it can be argued that the findings observed in the present
study may be driven by coincidental occurrence of AD, we found
that only 5 of the 105 PD subjects met a proposed CSF amyloid-






r= –0.18 r= –0.16 r= –0.10 r= –0.07
p= 0.028
Left hemisphere Right hemisphere
p= 0.32
p= 0.04 p= 0.05 p= 0.17 p= 0.25
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b Δ frontal
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Fig. 5 Relation to markers of cognitive decline. a Linear regression model
between changes (delta) in cortical thickness clusters and cognitive score
(MoCA). The overall model was significant; specifically, thinning of the left
frontal cluster (β= −0.23, p= 0.03) and age (β= 0.22, p= 0.01) were
significantly related to decline in cognitive performance. b Partial
correlations of CSF Aβ42 with thinning of each cortical thickness cluster
revealed significant correlations in the left hemispheric clusters. All
analyses controlled for age and gender
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synergy between Aβ42 and α-syn deposition promotes cognitive
impairment in PD50. Aβ42 has been found to promote gray matter
atrophy in distributed regions of the parietal and frontal lobe in
the normal aging brain51, akin to the atrophy pattern observed in
the present study; α-syn may accelerate the neurodegenerative
process associated with normal age-related Aβ42 deposition,
especially in regions connected to the PD disease reservoir.
The pattern of cortical atrophy in these de novo PD patients
may account for the constellation of mood and cognitive deficits
that eventually characterize PD dementia. Involvement of the
lateral prefrontal cortex and striatum could lead to executive
dysfunction. Inferior frontal areas also affected in behavioral
variant frontotemporal dementia may be implicated in apathy,
compulsive behaviors, changes in personality, and social deficits.
Finally, DMN involvement could account for Alzheimer-like
memory deficits while degeneration of ventral visual stream areas
could explain visual hallucinations. Using the Neurosynth pro-
gram and database52, we searched for the terms most often
associated in fMRI publications with each anatomical cluster
demonstrating atrophy in PD (Fig. 6). The left occipital–temporal
cluster is associated with (visual) motion, observation, perception,
and vision. The right somatomotor-sensory cluster is associated
with movement. The frontal clusters are associated with expres-
sions related to language and to the terms theory of mind, self,
social, mentalizing, and memory. The atrophic regions observed
here subserve the cognitive functions that fail in PD dementia.
Findings from this study should be considered in light of some
limitations. While the cellular events leading to changes in cor-
tical thickness are not clear, cortical thickness as measured with
T1-weighted MRI is nonetheless believed to reflect neuronal
density along with glial support and dendritic arborization53,54.
In PD, reductions in cortical thickness most likely reflect neu-
rodegeneration. In the current paper, we address the “protein-
spread” model, which we note remains controversial and lacking
in supportive human evidence6,7. With our current dataset and
imaging modalities, we cannot rule out the possibility of a sto-
chastic attack on the brain as a whole that would give the
appearance of network spread. Areas that are connected could
share features (e.g., gene expression55) that make them similarly
vulnerable to a specific pathophysiological process. In this case,
the map of atrophy would look like a network but not be driven
by connectivity. Additionally, neurodegeneration could propagate
due to loss of trophic factors having nothing to do with misfolded
protein spread. Moreover, we cannot measure α-syn accumula-
tion but only its consequence (cortical thinning), and the two
may have a complex and nonlinear relationship. However, the
present finding that a connectivity model explains disease pro-
gression better than chance lends support to the network-
propagation hypothesis. The inclusion criterion of MoCA> 26
may have biased both the PD and HC pool. Also, while our
sample is relatively large, the PPMI sample is a research-based
cohort and may not be truly representative of a population-based
cohort. Finally, most patients were prescribed dopaminergic
treatments after diagnosis, which may mask the magnitude of
cognitive decline and motor symptoms and their relationship
with brain atrophy. Future longitudinal studies and follow-up
with patients at later stages of the disease as well as postmortem
confirmation are needed to understand the relationship between
cortical atrophy and the underlying disease process.
The current study is the largest to date to assess longitudinal
measures of cortical thickness using 3 T MRI in a de novo PD
cohort. Our findings suggest that disease propagation to the
cortex occurs earlier than previously thought. Focal cortical
thinning may be contingent on connectivity to a disease reservoir:
the greater the connections, the higher the disease exposure, and
the more the cortical atrophy. PD progression involves sub-
cortical α-syn spreading through intrinsic brain networks to the
cortex, possibly in synergy with Aβ42, which may be the harbinger
of cognitive decline.
Methods
The PD patients included in this study met the PPMI inclusion criteria8 consisting
of asymmetric resting tremor or asymmetric bradykinesia or any two of bradyki-
nesia, resting tremor, and limb rigidity. Patients had to have been diagnosed within
2 years of enrollment and not have received anti-parkinsonian medications.
Diagnosis was confirmed with dopamine transporter imaging using single-photon
emission computed tomography. Control subjects were free of neurological disease.
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Each participating PPMI site received approval from their local institutional review
board and obtained written informed consent from all subjects. Analysis of this
dataset was approved by the Montreal Neurological Institute Research Ethics
Board. Only participants with 3 T MRI data at both initial visit and 1-year follow-
up were included in the present study. Of the 237 PD patients with 3 T acquisition
at baseline, 122 had MRI data at the 1-year follow-up. For controls, 118 subjects
had 3 T acquisition at baseline, and 62 had MRI data at the 1-year follow-up.
All non-categorical data were normally distributed as per Shapiro–Wilk tests.
Group difference in sociodemographic and neuropsychological variables were ana-
lyzed using the χ2 test for categorical data and t-test for normally distributed data.
MRI acquisition. T1-weighted MRI scans were acquired in the sagittal plane on 3 T
scanners at each study site using a magnetization-prepared rapid-acquisition gra-
dient echo sequence (full study protocol: http://www.ppmi-info.org/study-design/
research-documents-and-sops/). Acquisition parameters were as follows: repetition
time = 2300/1900 ms; echo time = 2.98/2.96/2.27/2.48/2.52 ms; inversion time =
900 ms; flip angle: 9°; 256 × 256 matrix; and 1 × 1 × 1mm3 isotropic voxel.
Acquisition site was used as a covariate in all analyses.
Cortical thickness. Cortical thickness models were generated from the T1-
weighted 3 T MRI scans using the CIVET2.1 preprocessing pipeline56. A summary
of the steps involved follows; full documentation can be found online (http://www.
bic.mni.mcgill.ca/ServicesSoftware/CIVET). The T1-weighted MRIs were linearly
registered to the MNI-ICBM152 volumetric template57,58. Images were then cor-
rected for signal intensity non-uniformity59, and a brain mask was calculated from
each input image. Images were then segmented into gray matter, white matter,
CSF, and background56. After the CIVET pipeline, quality control was carried out
by two independent reviewers using previously described criteria60 to ensure
adequate quality of the T1-wieghted volume images, such as linear and nonlinear
registration, and to exclude distortions in gray and white matter surfaces and
motion artifacts. Seventeen of the 122 PD and 5 of the 62 HC failed quality control.
The distance between the corresponding vertices of inner and outer cortical
surfaces were evaluated by a fully automated method (Constrained Laplacian
Anatomic Segmentation using Proximity algorithm61) to provide a measure of
cortical thickness at each vertex. The white and gray matter interface was fitted
across 40,692 vertices in each hemisphere to create the inner cortical surface, then
expanded to fit the gray matter and CSF interface to create the outer cortical
surface. The surfaces of each subject were nonlinearly registered to an average
surface created from the volumetric ICBM152 template. In order to test the
propagation hypothesis, the brain was segmented into 448 cortical and
15 subcortical regions29, and each of the 40,692 cortical vertices from the cortical
thickness analysis was interpolated and assigned to one of the 448 cortical parcels.
Changes in cortical thickness were calculated by subtracting the values (Δt=
t1−t2) at the 1-year follow-up (t2) from the baseline (t1) for both groups using the
SurfStat software package (http://www.math.mcgill.ca/keith/surfstat/). Difference
between PD and controls [(PD1-PD2)–(HC1-HC2)] were analyzed statistically
based on random field theory with a threshold of p< 0.05 corrected for multiple
comparisons over the entire cortical surface62.
In order to address the relationship between cognitive decline and cortical
thinning over the 1-year period, we performed a linear regression model. Change in
MoCA was the dependent variable, while mean cortical thinning values from each
of the four clusters distinguishing PD from controls were the independent
variables. Gender and age at baseline were used as covariates. Observed differences
in cortical thickness were then correlated to other potential disease-related
measures (i.e., UPDRS-III, MoCA, CSF α-syn, and tau and Aβ42 markers) using
Pearson partial correlations as post-hoc analysis. All the analyses were performed
using MatLab 2015b statistics toolbox. Within PD patients, the difference in
cognitive performance over the 1-year interval was examined using a linear
regression model with MoCA as the dependent variable and the thinning of the
four cortical clusters as independent variables.
To test whether cortical thickness of a specific cluster was linked to cognitive
performance, post-hoc analyses using partial correlations were conducted. Age at
baseline and gender were used as confounding covariates for all analyses including
for partial correlations, linear regression model, and for obtaining cortical thickness.
Deformation-based morphometry. Data were analyzed from the baseline visits of
newly diagnosed PD patients (n = 232) and an age-matched control group (n = 117)
obtained from the PPMI database. All subjects’ initial visit's 3 T high-resolution
T1-weighted MRI scans underwent preprocessing steps including denoising63,
intensity non-uniformity correction59, and intensity range normalization. Next,
each subject’s T1-weighted image was first linearly, and then nonlinearly, registered
to the MNI-ICBM152 template. Using the resulting nonlinear transformation
fields, we calculated deformation morphometry maps (i.e., the determinant of the
Jacobian matrix of transformation). DBM maps were then concatenated and
independent component analysis (ICA) was employed to define independent
sources of deformation in the brain. For the resulting ICA components (n = 30), the
PD group was compared to healthy controls (unpaired t-test). The atrophy level
significantly differed between PD and control groups in only one of these com-
ponents after correcting for multiple comparisons (Bonferroni correction),
suggesting that this component captures PD-specific alterations in the brain. We
used this component (referred to as PD-ICA here) as our atrophy map. The
component score (atrophy measure) in PD-ICA for each subject was significantly
correlated with disease severity as measured by UPDRS-III and single-photon
emission computed tomography striatum binding ratio. Please see Zeighami et al.9
for further details.
Connectivity and disease propagation. The difference in cortical thinning in PD
vs controls was used to define disease progression. DBM on the baseline MRI was
employed to assess disease-related brain atrophy and to define a source, or
reservoir, for disease propagation. Based on a parcellation that is a subdivision of
the common FreeSurfer implementation of the Desikan–Killiany Atlas, gray matter
was segmented into 463 regions of interest of approximately similar size29. Of these
parcels, 448 were cortical and 15 were subcortical (thalamus, caudate, putamen,
pallidum, accumbens, hippocampus, amygdala in each hemisphere and brainstem).
Each surface vertex from the cortical thickness analysis was then mapped to the
corresponding nearest whole-brain parcel from the Atlas. The “disease reservoir”
was defined as the 15 subcortical parcels from the Atlas, and the Atrophy value at
each parcel was obtained from the DBM map.
To generate brain networks and connectomes, data-driven brain parcellations
from young healthy individuals were used29. The functional connectivity map was
derived from resting-state fMRI data of 40 young healthy subjects (25.3± 4.9 years,
24 males)64. The scans were done using Siemens Medical Trio 3 T MRI scanner,
consisting of a high-resolution T1-weighted image, as well as T2*-weighted images
with blood-oxygen-level-dependent contrast (3.3 mm3 isotropic voxels, TR 1.9 s).
The dataset was preprocessed using conventional steps consisting of rigid body
motion correction, correcting for nuisance variables (white matter, CSF, motion
parameters), and low pass filtering. The structural connectivity map was generated
using the Illinois Institute of Technology Human Brain Atlas v.3, (freely available
at http://www.iit.edu/~mri/Home.html). The atlas was constructed using data from
72 neurologically healthy subjects (20–40 years, 28.8± 5.5 years, 30 males). All
subjects were scanned using a 3 T General Electric MRI scanner (GE, Waukesha,
WI) with the following parameters (TR = 5800 ms, TE = 94ms, voxel size = 3 mm3,
256 × 256 final image matrix, FoV = 24 × 24 cm2, b = 900 s mm−2, 45 slices for 12
diffusion directions uniformly distributed in 3D space, scan time: 21 min 57 s)65.
Imposing a maximum of 500 mm trace length and a curvature threshold of ±90,
the anatomical connection probability was calculated between all pairs of regions
using a probabilistic graph-based tractography algorithm66.
Spearman’s correlation was used to investigate the relationship between disease
progression in cortical areas (cortical thinning) and the ‘disease exposure’ for each
region in the PD-ICA (defined by the average values of each region weighted by
connectivity). The same procedure was performed to test propagation hypotheses
along the functional and structural connectomes. The propagation analysis was
performed for the whole brain and for each hemisphere separately.
CSF measures. CSF Aβ42, α-syn, t-tau, and p-tau181 were collected by lumbar
puncture at PPMI clinical sites67. Frozen aliquots (at −80 °C) were then shipped
and assessed using the MAP Luminex platform (Luminex Corp, Austin, TX)
with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research use-only
reagents) immunoassays used for Aβ42, t-tau and p-tau181. CSF α-syn assay was
performed at Covance using a commercially available ELISA Assay Kit (Covance,
Dedham, MA)68. To evaluate the possible contamination of blood in CSF—a factor
thought to influence the level of some proteins including α-syn and Aβ4269,70—the
relationship between CSF hemoglobin and other CSF measures was assessed. No
significant association was observed (all p< 0.05), suggesting that there is no effect
of added blood on concentration of CSF measures. Owing to the ongoing nature of
the study and incomplete data, only CSF data from baseline were used in this
analysis68.
Code availability. All code written by the authors of this manuscript is available
upon request.
Data availability. The DBM maps are available at https://neurovault.org/
collections/860/. Cortical thickness maps will be made available on request. The
CIVET pipeline is available at http://www.bic.mni.mcgill.ca/ServicesSoftware/
CIVET. The functional and structural connectome data are from cited sources and
available upon request from the authors of the related publications.
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